Published in Int J Biol Sci on February 06, 2016
OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | NCT01685268
Open Label Prostate Cancer Study | NCT01162395
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | NCT02012920
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer | NCT01647789
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy | NCT00470834
ARTS - AVODART After Radical Therapy For Prostate Cancer Study (ARTS) | NCT00558363
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer | NCT00286806
An Open Label Prostate Cancer Study in Japanese Patients | NCT01351688
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy. Cancer Cell Int (2017) 0.75
Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer. Cancer Med (2016) 0.75
Androgen receptor splice variants and prostate cancer: From bench to bedside. Oncotarget (2017) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 8.73
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med (1992) 7.16
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (1988) 3.96
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int (2008) 3.94
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol (2014) 3.44
Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science (1988) 3.40
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 2.94
Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer (1973) 2.91
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 2.87
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun (1971) 2.67
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med (2000) 2.65
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
Selective retention of dihydrotestosterone by prostatic nuclei. Nature (1968) 2.60
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Biology of prostate-specific antigen. J Clin Oncol (2003) 2.44
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem (1994) 2.35
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem (2000) 2.31
Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest (1983) 2.25
The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem (2004) 2.15
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res (2014) 2.10
The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem (1998) 2.08
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem (1996) 2.05
The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol (1999) 2.00
Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem (1999) 2.00
The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem (1968) 1.98
Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A (2004) 1.97
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther (2008) 1.95
Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem (2002) 1.95
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol (2004) 1.86
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol (1997) 1.85
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther (2013) 1.81
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem (2005) 1.80
Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res (2011) 1.77
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.77
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell (2009) 1.77
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol (1999) 1.70
Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand. J Med Chem (2000) 1.69
An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol (1997) 1.63
Activation of nuclear receptors: a perspective from structural genomics. Structure (2003) 1.59
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer (2013) 1.57
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol (2000) 1.50
Hormonal therapy: historical perspective to future directions. Urology (2003) 1.49
Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem (2003) 1.42
A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide). Endocrinology (1972) 1.40
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol (2015) 1.39
The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel? J Clin Oncol (2015) 1.38
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol (2012) 1.38
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res (2009) 1.36
An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem (2004) 1.36
Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol (2012) 1.34
An overview on 5alpha-reductase inhibitors. Steroids (2009) 1.29
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (2012) 1.28
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem (2011) 1.27
Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol (2011) 1.23
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol (1989) 1.21
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol (2013) 1.21
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Antiandrogens prevent stable DNA-binding of the androgen receptor. J Cell Sci (2005) 1.16